Catalyst Pharmaceuticals, Inc.CPRXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-39.03%
↓ 172% below average
Average (39q)
54.11%
Historical baseline
Range
High:2015.88%
Low:-97.64%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -39.03% |
| Q2 2025 | 12.12% |
| Q1 2025 | 2.34% |
| Q4 2024 | 15.65% |
| Q3 2024 | 10.02% |
| Q2 2024 | 15.65% |
| Q1 2024 | 30.88% |
| Q4 2023 | -97.64% |
| Q3 2023 | 2015.88% |
| Q2 2023 | 11.01% |
| Q1 2023 | -12.97% |
| Q4 2022 | -50.75% |
| Q3 2022 | 108.64% |
| Q2 2022 | 17.04% |
| Q1 2022 | -31.83% |
| Q4 2021 | 11.25% |
| Q3 2021 | 0.83% |
| Q2 2021 | 47.99% |
| Q1 2021 | -27.98% |
| Q4 2020 | 11.36% |
| Q3 2020 | -13.81% |
| Q2 2020 | 3.00% |
| Q1 2020 | -33.06% |
| Q4 2019 | 37.23% |
| Q3 2019 | -0.70% |
| Q2 2019 | 39.95% |
| Q1 2019 | -60.70% |
| Q4 2018 | 85.46% |
| Q3 2018 | 22.50% |
| Q2 2018 | 13.68% |
| Q1 2018 | -4.28% |
| Q4 2017 | 25.87% |
| Q3 2017 | 10.33% |
| Q2 2017 | -12.87% |
| Q1 2017 | -0.24% |
| Q4 2016 | 13.10% |
| Q3 2016 | -0.59% |
| Q2 2016 | -29.25% |
| Q1 2016 | -7.44% |
| Q4 2015 | 25.93% |